Original Research
Accepted on 30 Sep 2025
The 41BB-agonist potentiates the therapeutic efficacy of a combined irreversible electroporation ablation treatment of lung cancer by promoting unexpected CD8+CD103+ cDC1 and tissue-resident memory T cell responses
in Cancer Immunity and Immunotherapy